Table 3.
Antibody titers in HLA class II alleles and haplotypes
| Allele/haplotype | Antibody titera |
|||||||
|---|---|---|---|---|---|---|---|---|
| Anti-GAD |
Anti-IA2 |
|||||||
| Positive | Negative | Z | P | Positive | Negative | Z | P | |
| DRB1*030101 | 73.10 ± 59.51 | 28.16 ± 17.08 | 3.87 | <0.001 | 30.90 ± 24.52 | 21.89 ± 20.49 | 0.58 | 0.521 |
| DRB1*040101 | 64.83 ± 52.68 | 52.93 ± 40.52 | 1.26 | 0.209 | 63.44 ± 56.44 | 25.20 ± 25.34 | 1.73 | 0.007 |
| DRB1*070101 | 37.34 ± 21.42 | 60.08 ± 31.45 | −3.30 | 0.001 | 20.94 ± 11.27 | 42.08 ± 31.45 | −1.45 | 0.146 |
| DRB1*110101 | 11.24 ± 4.35 | 58.62 ± 43.92 | −3.51 | <0.001 | 27.42 ± 12.80 | 58.48 ± 28.71 | −2.57 | 0.010 |
| DQB1*030101 | 17.22 ± 14.03 | 56.79 ± 39.74 | −3.01 | 0.001 | 13.12 ± 12.87 | 29.77 ± 27.29 | −1.73 | 0.083 |
| DRB1*060101 | 26.68 ± 24.27 | 53.22 ± 49.19 | −1.32 | 0.031 | 16.57 ± 15.21 | 29.41 ± 27.52 | −0.07 | 0.365 |
| DRB1*030101/DQB1*0201 | 114.72 ± 42.99 | 24.09 ± 25.39 | 2.77 | <0.001 | 43.61 ± 44.71 | 29.14 ± 31.79 | 1.01 | 0.257 |
| DRB1*040101/DQB1*0302 | 111.29 ± 49.97 | 52.12 ± 38.92 | 0.786 | 0.007 | 69.22 ± 53.07 | 25.17 ± 25.01 | 2.52 | 0.001 |
| DRB1*070101/DQB1*0201 | 19.34 ± 15.36 | 60.24 ± 56.90 | −3.24 | 0.001 | 25.17 ± 13.81 | 40.98 ± 30.42 | −0.92 | 0.359 |
| DRB1*110101/DQB1*030101 | 17.32 ± 15.56 | 98.30 ± 50.10 | −3.25 | 0.001 | 15.89 ± 10.52 | 31.83 ± 23.81 | −2.21 | 0.025 |
Positive, patients carrying the specific allele/haplotype; negative, other patients; Z, Z score. The values are mean ± SD antibody titers (AU/ml); differences in antibody titers between the patient groups were determined using a two-tailed Student t test.